TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10945511
Drug: Estradiol matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol matrix transdermal system (0.0375 mg/d)
Study: 10945511
Drug: Estradiol matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol matrix transdermal system (0.025 mg/d)
Study: 10945511
Drug: Estradiol matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol matrix transdermal system (all doses)
Study: 1308130
Drug: Intensive control
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive control with a step-up regimen including insulin alone or insulin/glipizide combinations
Study: 1308130
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy group with insulin
Study: 6363659
Drug: Antenatal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antenatal dexamethasone administration
Study: 3890036
Drug: Mepivacaine carbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine carbonate (1% solution)
Study: 29266879
Drug: Celecoxib (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100-200 mg twice daily)
Study: 29266879
Drug: Ibuprofen (600-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600-800 mg 3 times daily)
Study: 31448533
Drug: Lactulose (Gp-L)
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose (Gp-L)
Study: 31448533
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (Gp-NL)
Study: 29231522
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of moxibustion along the governor vessel and the conception vessel with salazosulfapyridine (SASP)
Study: 29231522
Drug: Routine moxibustion
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine moxibustion therapy
Study: 20179727
Drug: Phytosphingosine (PS)
DrugBank: Phytosphingosine (DB14119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosphingosine (PS) 500 mg twice daily
Study: 12487780
Drug: F(ab')(2) FRaMon
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: F(ab')(2) FRaMon 0.2 mg/kg
Study: 12487780
Drug: F(ab')(2) FRaMon
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: F(ab')(2) FRaMon 0.25 mg/kg
Study: 7865980
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 5.7, 11.4, and 17.1 pmol kg‐1 min‐1 CDD/ANP‐99‐126
Study: 7865980
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of CDD/ANP‐99‐126
Study: 2673438
Drug: Monthly three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly three day course with adriamycin (ADM), cyclophosphamide (CPM), vindesine (VDS) and 5 fluoro‐uracil (5 FU)
Study: 2673438
Drug: Fractionated schedule
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated schedule with 4 injections of ADM, CPM, VDS and continuous infusion of 5 FU over 10 days
Study: 22392354
Drug: Lichtenstein technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lichtenstein technique (L)
Study: 19672152
Drug: gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine plus LY293111 (LY) 600 mg twice daily
Study: 17502466
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal system (2, 4, or 6 mg during 24 hours for 24 weeks)
Study: 21080009
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal system
Study: 15031343
Drug: Alfacalcidol treatment
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol treatment
Study: 12153335
Drug: Ziprasidone 80
Normalized name: ziprasidone 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 80 or 160 mg/day
Study: 12153335
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 to 160 mg/day
Study: 12153335
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral ziprasidone treatment
Study: 9222908
Drug: Ulnar L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulnar L incision
Study: 3665218
Drug: Isosorbide-5-mononitrate (ISMN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (ISMN) 40 mg
Study: 8699777
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 40 mg
Study: 30357437
Drug: Ketamine (subanesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (subanesthetic dose, target plasma level 100 ng/ml)
Study: 23674608
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rifampicin
Study: 23674608
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rifampicin
Study: 23674608
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rifampicin
Study: 19767711
Drug: Psychiatric drug
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric drug therapy in addition to topical corticosteroids
Study: 19767711
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids only (Control)
Study: 19767711
Drug: Psychiatric drug
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric drug therapy
Study: 16553140
Drug: Psychosocial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial therapy (PST; physical activity control) 3 times/wk for 12 weeks
Study: 12692051
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg twice daily (n=259)
Study: 11083356
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy (1.06-microm continuous wave laser emitting 204 mW/cm2 for 60 seconds at 7 points along the symptomatic forearm, 3 times weekly for 4 weeks)
Study: 11083356
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (inactive laser treatment)
Study: 11083356
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy
Study: 24447183
Drug: HTNV DNA
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTNV DNA vaccine (2.0 mg total dose, 1 mL saline, administered on days 0, 28, and 56)
Study: 24447183
Drug: PUUV DNA
Normalized name: PUUV DNA vaccine
DrugBank: Puumala virus DNA vaccine (DB17809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUUV DNA vaccine (2.0 mg total dose, 1 mL saline, administered on days 0, 28, and 56)
Study: 24447183
Drug: Combined HTNV
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HTNV and PUUV DNA vaccines (1.0 mg each, 2.0 mg total dose, 1 mL saline, administered on days 0, 28, and 56)
Study: 19762206
Drug: Combined Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Therapy (PTA + SEP)
Study: 27630092
Drug: Four implants
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four implants
Study: 27630092
Drug: Six implants
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six implants
Study: 25536639
Drug: TVR-standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVR-standard group (2,250 mg TVR for 12 weeks plus reduced ribavirin dose)
Study: 25536639
Drug: TVR-reduced group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVR-reduced group (1,500 mg TVR plus standard ribavirin dose)
Study: 21481003
Drug: New gustatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: New gustatory stimulant of salivary secretion (GSSS) containing weaker malic acid, fluoride, and xylitol
Study: 21481003
Drug: Traditional citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional citric acid-based gustatory stimulant of salivary secretion (GSSS)
Study: 10714690
Drug: Combination cyclopentolate
Normalized name: cyclopentolate, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cyclopentolate 0.2% and phenylephrine 1% eyedrops
Study: 1576488
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU of salmon calcitonin and 500 mg of elemental calcium for 10 consecutive days each month
Study: 1576488
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of elemental calcium only for 10 consecutive days each month
Study: 30982716
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication (paracetamol, opioids, or both)
Study: 27041272
Drug: Subtenon block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtenon block with mixture of 4 mL of 2% lidocaine and 0.5% bupivacaine (50:50)
Study: 27041272
Drug: Subtenon injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtenon injection of saline
Study: 23996878
Drug: Postoperative intensity‐modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative intensity‐modulated radiation therapy (IMRT)
Study: 22499521
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide intramuscular injection after swallowing the capsule
Study: 22499521
Drug: No metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: No metoclopramide administered (Control)
Study: 22499521
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide intramuscular injection
Study: 20727717
Drug: Focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused treatment groups (various interventions)
Study: 20727717
Drug: Control UHR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control UHR groups (no treatment or treatment as usual)
Study: 20727717
Drug: Any focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any focused treatment
Study: 16199148
Drug: Formoterol 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 9 microg bid plus terbutaline 0.5 mg as needed (FORM bid)
Study: 16199148
Drug: Placebo bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid plus terbutaline 0.5 mg as needed (placebo)
Study: 10626340
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + complex of amino acids (100 mg 3 times a day sublingually)
Study: 10626340
Drug: Adjuvant preductal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant preductal (20 mg 3 times a day per os for 20 days)
Study: 10626340
Drug: Conventional antianginal
Normalized name: ANTIANGINALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antianginal therapy (nitrates, beta-adrenoblockers, calcium antagonists, diuretics, ACI inhibitors, cardiac glycosides, and aspirin)
Study: 23383726
Drug: Group counseling
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group counseling intervention (problem-solving therapy approach)
Study: 15598478
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination latanoprost 0.005% + timolol maleate 0.5% QD
Study: 11121915
Drug: ABT-229 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-229 1.25 mg
Study: 11121915
Drug: ABT-229 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-229 2.5 mg
Study: 11121915
Drug: ABT-229 5
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-229 5 mg
Study: 11121915
Drug: ABT-229 10
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-229 10 mg
Study: 8173702
Drug: Diltiazem (180-360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180-360 mg daily)
Study: 8173702
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (diuretics or beta-adrenergic blockers)
Study: 3507007
Drug: Beef extended
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef extended with soy products fortified with 60 mg Fe and 25 mg Zn/100 g protein
Study: 29534403
Drug: Regular dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dosage of fasudil (30 mg)
Study: 29534403
Drug: Large dosage
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large dosage of fasudil (60 mg)
Study: 29534403
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between large dosage and regular dosage groups
Study: 26603174
Drug: Artesunate-mefloquine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-mefloquine (target dose 12 mg/kg artesunate and 25 mg/kg mefloquine)
Study: 26603174
Drug: Chloroquine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (target dose 25 mg/kg)
Study: 16962170
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin users
Study: 16962170
Drug: Regular acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular acetaminophen users
Study: 16962170
Drug: Greater frequency
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater frequency of acetaminophen use (>7 tablets weekly)
Study: 16962170
Drug: Greater duration
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater duration of acetaminophen use (>10 years)
Study: 20689457
Drug: 6.4% carbohydrate‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% carbohydrate‐electrolyte solution (CHO)
Study: 7604806
Drug: Fluvastatin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin at 20 mg twice daily
Study: 7604787
Drug: Gemfibrozil at
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil at 600 mg twice daily
Study: 7604787
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluvastatin and gemfibrozil
Study: 2123072
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) administered within 4 hours from symptom onset (group A)
Study: 2123072
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) administered between 4 and 8 hours from symptom onset (group B)
Study: 360249
Drug: Carbamazepine (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (300-600 mg daily for six weeks)
Study: 31324444
Drug: Thymoglobulin induction
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin induction with tacrolimus and/or mycophenolate mofetil maintenance, steroids not used beyond 1 week
Study: 16116596
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist treatment
Study: 20150283
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CON)
Study: 10419922
Drug: Methotrexate 7.5
Normalized name: methotrexate 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 7.5 mg/wk
Study: 2186776
Drug: Papaverine 100
Normalized name: papaverine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine 100 mg q.d.s. orally for 4 weeks
Study: 28162984
Drug: Eltrombopag (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (50 mg to 300 mg)
Study: 16278621
Drug: Group education
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group education and an educational booklet on the first day of therapy, counseling in the third and sixth months
Study: 12036860
Drug: Idarubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin plus continuous-infusion, high-dose cytosine arabinoside (IA)
Study: 7000222
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (300 mg intramuscularly per week)
Study: 7000222
Drug: Oestradiol undecylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol undecylate (100 mg intramuscularly per month)
Study: 9722227
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate 0.1 mg o.d. (n=26)
Study: 9722227
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate 0.2 mg o.d. (n=25)
Study: 8036306
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no inhaled steroids)
Study: 2730826
Drug: Undiluted i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undiluted i.m. preparation (25 mg ml‐1)
Study: 2730826
Drug: Diluted i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted i.m. preparation in normal saline (5 mg ml‐1)
Study: 16091396
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg/6 weeks)
Study: 10676476
Drug: Selenium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium concentration in serum (55 +/- 11 micrograms Se/L)
Study: 10676476
Drug: Selenium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium concentration in hair (0.268 +/- 0.040 microgram Se/g)
Study: 10676476
Drug: Selenium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium concentration in urine (12 +/- 5 micrograms Se/L)
Study: 7573869
Drug: Different end-tidal
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different end-tidal carbon dioxide and volatile agent concentrations during maintenance of anaesthesia
Study: 29756749
Drug: Flurbiprofen oral
Normalized name: flurbiprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen oral spray
Study: 29756749
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride oral spray
Study: 27115264
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement intervention including daily checklist and goal setting during multidisciplinary rounds with follow‐up clinician prompting for 11 care processes
Study: 25214161
Drug: Nutritional education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional education and supplemental iron administration (iron polymaltose complex)
Study: 25214161
Drug: Iron medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron medication for >6 months
Study: 17285386
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg after induction of anesthesia
Study: 17285386
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg just before the end of anesthesia
Study: 17285386
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg after induction of anesthesia and Metoclopramide 10 mg before the end of anesthesia
Study: 16583989
Drug: Standard Antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Antibiotic Therapy (SAT) combined with amikacin
Study: 16583989
Drug: Other Antibiotic
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Antibiotic Therapy (OAT) combined with amikacin
Study: 16583989
Drug: Amikacin used
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin used in high once daily dose (HODD) with SAT or OAT
Study: 16583989
Drug: Direct costs
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct costs of treatment with SAT
Study: 16583989
Drug: Direct costs
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct costs of treatment with OAT
Study: 16583989
Drug: Overall cost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall cost reduction by introducing safe and cheap standard treatment
Study: 815188
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg
Study: 1600043
Drug: Micronutrient antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient antioxidant therapy (600 micrograms organic selenium, 9000 i.u. beta-carotene, 0.54 g vitamin C, 270 i.u. vitamin E, 2 g methionine)
Study: 2103755
Drug: Micronutrient antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient antioxidant therapy
Study: 30871594
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg twice daily for 28 ± 2 days
Study: 30643068
Drug: Fluvoxamine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine combined with extended-release methylphenidate (MPH-ER)
Study: 27789196
Drug: Local consolidative
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local consolidative therapy (chemo/radiotherapy or resection of all lesions)
Study: 27789196
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment alone (could be observation)